Manufacturing Fixed, But Trial Interpretability Now Blocks US Approval

Drug & Indication Overview

Atara Biotherapeutics (NASDAQ:ATRA) has developed Ebvallo (tabelecleucel), a novel second-line immunotherapy for Epstein–Barr virus–positive post-transplant lymphoproliferative disease (EBV-PTLD).

The BLA is primarily supported by data from the Phase 3, single-arm, open-label ALLELE trial (NCT03394365). In the ALLELE trial, Ebvallo met its prespecified primary efficacy endpoint and demonstrated a generally tolerable safety profile.

The Regulatory Timeline

It is noteworthy that Ebvallo had already received European Commission marketing authorization in the EU on 16 December 2022.

In the U.S., Ebvallo previously received a CRL on January 15, 2025, which identified a single manufacturing compliance deficiency and did not raise concerns regarding safety, efficacy, or trial design.

On January 9, 2026, Atara received a second FDA Complete Response Letter (CRL) for the Biologics License Application (BLA) for Ebvallo.

Second CRL: Core Issue

The BLA is primarily supported by data from the Phase 3, single-arm, open-label ALLELE trial (NCT03394365). In the ALLELE trial, Ebvallo met its prespecified primary efficacy endpoint and demonstrated a generally tolerable safety profile.

In the new CRL, the previously cited manufacturing deficiencies were resolved. However, the FDA stated that it cannot approve the BLA in its current form, citing concerns that the ALLELE trial is no longer considered adequate to demonstrate effectiveness for accelerated approval due to interpretability issues related to trial design, conduct, and analysis.

Notably, this CRL is not driven by manufacturing or safety issues, nor by a failed efficacy signal in the current data. Instead, it reflects a change in the FDA's assessment of whether the existing dataset is considered sufficient to support accelerated approval.

What Comes Next

Atara is currently at an extremely constrained net liquidity level. However, Atara has already monetized a portion of its Ebvallo EU royalty and certain milestone economics through the HCRx royalty-interest transaction. As Ebvallo has now been rejected by the FDA, the company may have very few remaining unencumbered assets or cash-flow streams left to sell or finance in the near term.

Given the information in the CRL, the most likely path forward is that Atara and Pierre Fabre Pharmaceuticals, which assumed sponsorship of the BLA from Atara in November 2025, will need to conduct an additional clinical trial to address the FDA's concerns.

Speaking of cost, the new trial's direct cost burden most likely sits with Pierre Fabre, not Atara. However, SEC filings note that Atara agreed to provide and/or extend certain services to Pierre Fabre at Atara's cost, which still makes Atara economically impacted. As the FDA wants a more credible design to remove "confounding," this may result in requiring a randomized or more stringent confirmatory design, which can push timelines toward 2–3 years.

Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.